Phase 1 Study Investigating Effects of HTL0009936 on Cognition and BOLD fMRI Signals in Healthy Elderly Subjects
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
To determine if treatment with HTL0009936 will lead to changes in neural activity, measured using the fMRI BOLD signal and ASL, in brain areas that are associated with spatial and working memory, learning and executive functioning.
Interventional, Randomised, Double-blind, Parallel-group, Placebo-controlled, Phase 1, Exploratory Study Investigating the Effects of HTL0009936 on Cognition and BOLD fMRI Signals in Healthy Elderly Subjects
Study Start Date :
Actual Primary Completion Date :
Actual Study Completion Date :
Resource links provided by the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
65 Years to 80 Years (Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Healthy on the basis of medical history, physical examination, vital signs, 12-lead ECG, haematology, blood chemistry, urinalysis and a pre-study psychological assessment.
Mini Mental State Examination (MMSE) Score of ≥24.
Intermediate or extensive metaboliser as determined by CYP2D6 genotype.
Fluent English speaker.
Not a regular smoker
Recreational drug use within 3 months prior to Screening Visit.
Positive alcohol breath test.
Positive urine drug screen.
Consumption of large amounts of caffeinated drinks.
Consumption of any food or any drinks containing cranberry, pomegranate, star fruit, grapefruit, pomelos, exotic citrus fruits or Seville oranges.
Ultra-rapid or poor metabolizer as determined by CYP2D6 genotype.
By self-report, taking two or more daytime naps per week which in the opinion of the investigator is likely to interfere with the ability of the subject to complete the study procedures.
History of, or presents (in the opinion of the Investigator) with, significant neurological or psychiatric conditions.
Personal or family history of congenital long QT syndrome or sudden death.
Concomitant use of drugs that are metabolised by and/or are inhibitors of CYP2D6.
Concomitant use of drugs that are substrates for the organic cation transporter 2.
History of significant claustrophobia.
Fulfils any of the MRI contraindications on the standard site radiography screening questionnaire (e.g. history of surgery involving metal implants).